- Explain the diagnostic criteria for this disorder
- Explain the evidenced-based psychotherapy and psychopharmacologic treatment for Mild vascular neurocognitive disorder.
- Identify the risks of different types of therapy and explain how the benefits of the therapy that might be achieved might outweigh the risks.
- Support your rationale with references to the Learning Resources or other academic resource.
Required Readings( Need 3 + references).
Acadia Pharmaceuticals. (2017). Transform the treatment of Parkinson’s disease psychosis with NUPLAZID. Retrieved from https://www.nuplazidhcp.com/?gclid=CIHS5auvwtMCFQkaaQodrU0FGQ
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Washington, DC: Author.
· “Neurocognitive Disorders”
Gabbard, G. O. (2014). Gabbard’s treatment of psychiatric disorders (5th ed.). Washington, DC: American Psychiatric Publications.
· Chapter 63, “Delirium”
· Chapter 64, “Neurocognitive Disorder Due to Alzheimer’s Disease”
· Chapter 65, “Frontotemporal Neurocognitive Disorder”
· Chapter 66, “Vascular Neurocognitive Disorder”
· Chapter 67, “Neurocognitive Disorder Due to Parkinson’s Disease”
Hopkins, S. A., & Chan, D. (2016). Key emerging issues in frontotemporal dementia. Journal of Neurology, 263(2), 407–413. doi:10.1007/s00415-015-7880-7
Sadock, B. J., Sadock, V. A., & Ruiz, P. (2014). Kaplan & Sadock’s synopsis of psychiatry: Behavioral sciences/clinical psychiatry (11th ed.). Philadelphia, PA: Wolters Kluwer.
· Chapter 21, “Neurocognitive Disorders” (pp. 694–741)
Stahl, S. M. (2017). Prescriber’s Guide: Stahl’s Essential Psychopharmacology (6th ed.). New York, NY: Cambridge University Press.
